Today in @ScienceMagazine, together with my former colleagues at NIBR, we report the discovery and characterization of first molecular glue degraders of the WIZ transcription factor (TF) for fetal hemoglobin derepression and therapeutic consideration in Sickle Cell Disease. 1/10
Jay Bradner, M.D.
2,601 posts
Physician-scientist making medicines with friends, memories with family. EVP R&D at Amgen
- Bob Bradway announced today that I have joined his leadership team as Executive Vice President of R&D, and Chief Scientific Officer @Amgen. I am overjoyed by the opportunity to create and develop therapeutic solutions for patients with serious illnesses. Here are some additionalWe’re announcing two changes to Amgen’s senior leadership team that will keep our company at the forefront of innovation. @jaybradner, M.D., joins as EVP, R&D, and Chief Scientific Officer. David M. Reese, M.D., will assume a new role as EVP and Chief Technology Officer.
00:00 - When I joined NIBR 7 years ago, my beloved predecessor Mark Fishman wisely said: "For things to remain as good, things will surely have to change." This rings true today as I share news that I will step down as President of NIBR on Oct 31. Read more: tinyurl.com/35xv2kpd 1/7
- As seen driving in for morning rounds on the stem cell transplant service at @DanaFarber. Honk honk, and congratulations.
- Not the first breakfast we’ve talked about CRISPR, but for sure the first explaining the Nobel Prize. Love that our girls will forever have two women as their frame of reference.
- A gem for those who still debate academia “versus” industry. The present reality is that all in industry were once in academia, as trainees or scholars, and many in industry will return to teach, advise, investigate. The era of the One Way ticket is firmly over, buy the bus pass!Traversing industry and academia in biomedicine: the best of both worlds? go.nature.com/3LXgy7A #Viewpoint by Gary Gilliland @fredhutch, Aviv Regev @genentech, Eric Schadt @sema4 & @joyceytung @23andMe
- Excited to welcome @HowardYChang to @Amgen as our new SVP for Research & CSO! A pioneering physician-scientist, Howard’s expertise in genetics, oncology, & inflammation will help us push the boundaries of discovery. We’re excited to embark on this journey together to redefine the
- The only barrier to biomedical innovation in Cambridge is the Cambridge-Allston Exit on the Mass Pike.
- Devastated by the passing of Jose Baselga. A champion of cancer research, a passion for people and life, a brilliant light out far too soon. Rest in peace, Jose, we will miss your joy and your tireless ambition to do more for cancer patients.
- Maybe the most lovely reflection on a life well lived, amidst a cancer diagnosis, that I’ve ever read. By Simon Boas. jerseyeveningpost.com/news/2024/02/1…
- It’s not every day that your team gets to be a part of history. Today our #CARTcell therapy was approved by the #FDA bddy.me/2iJS9sZ
- I have a PROTAC joke, but it’s degrading.









